Accuray Inc.

433 articles with Accuray Inc.

• Accuray CyberKnife® Robotic Radiotherapy Platform Expands Range of Neurological Indications That Can Be Effectively Treated With Stereotactic Radiosurgery

  11/10/2021

  Accuray Incorporated (NASDAQ: ARAY) announced today that more than two decades of globally-driven clinical data support the use of the company's CyberKnife® robotic radiotherapy platform for the delivery of stereotactic radiosurgery (SRS) treatments for neurological diseases.

• Accuray To Participate at Stifel 2021 Virtual Healthcare Conference

  11/9/2021

  Company to present on Tuesday, November 16th, 2021 at 6:20 am PT / 9:20 am ET

• Accuray Reports Fiscal 2022 First Quarter Financial Results

  11/3/2021

  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2022 ended September 30, 2021 .

• Accuray CyberKnife® Robotic Radiotherapy Platform Could Significantly Improve Survival in Early-Stage Breast Cancer Patients

  10/25/2021

  Accuray Incorporated  (NASDAQ: ARAY) announced today that a study published in Frontiers in Oncology  found early-stage breast cancer patients could experience significant improvements in survival if treated with accelerated partial breast irradiation (APBI) delivered using the Accuray CyberKnife

• Accuray Announces Preliminary First Quarter Fiscal 2022 Financial Results and Raises FY22 Revenue Guidance to range between $420 million to $427 million

  10/21/2021

  Accuray Incorporated, announced preliminary financial results for the first quarter of fiscal 2022 ended September 30, 2021.

• Accuray Unveils VOLO™ Ultra, the Latest Innovation for the Radixact® System, at ASTRO 2021

  10/19/2021

  Accuray Incorporated (NASDAQ: ARAY) announced today the company is showcasing its new VOLO™ Ultra for the Radixact ® System, at ASTRO 2021.

• Accuray to Report First Quarter Fiscal 2022 Financial Results on November 3, 2021

  10/13/2021

  Accuray Incorporated (NASDAQ: ARAY) will report financial results for the first quarter of fiscal year 2022, ended September 30, 2021 , after the market close on Wednesday, November 3, 2021

• Accuray to Host ASTRO Analyst & Investor Meeting on October 25, 2021

  10/12/2021

  Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host an Analyst & Investor Meeting on Monday, October 25, 2021 , in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting.

• Nagoya City University Hospital is First in Japan to Treat Cancer Patients Using the Accuray Radixact® System with ClearRT™ Helical Fan-Beam kVCT Imaging

  9/23/2021

  Accuray Incorporated (NASDAQ: ARAY) announced today that the Nagoya City University Hospital in Aichi has treated the first cancer patient in Japan using the Radixact ® System with ClearRT

• Mika Nishimura Joins Accuray Board of Directors

  8/23/2021

  Accuray Incorporated announced the appointment of Mika Nishimura to the company's Board of Directors, effective as of August 17, 2021.

• Accuray Reports Fourth Quarter and Fiscal 2021 Financial Results

  8/11/2021

  Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the fourth quarter and fiscal year ended June 30, 2021 .

• Hong Kong Sanatorium & Hospital Transforms Cancer Care in Asia with Treatment of First Patient Using the Accuray Radixact® System and ClearRT™ Helical Fan-Beam kVCT Imaging

  7/22/2021

  Accuray Incorporated (NASDAQ: ARAY) announced today that the medical care team at Hong Kong Sanatorium & Hospital  (HKSH) in Hong Kong treated the first cancer patient in using the Radixact® System, the next-generation TomoTherapy® platform, with ClearRT™ helical fan-beam kVCT imaging.

• Accuray to Report Fiscal Year-End 2021 Financial Results on August 11, 2021

  7/14/2021

  Accuray Incorporated will report financial results for the fourth quarter and fiscal year 2021, ended June 30, 2021, after the market close on Wednesday, August 11, 2021.

• Beloved Family Pet's Lung Cancer is Treated with Targeted Radiotherapy Using the Accuray Radixact® System with Synchrony® Technology

  6/24/2021

  The University of Wisconsin-Madison School of Veterinary Medicine team is advancing cancer care as the first to treat an animal using the Radixact® System with Synchrony®.

• Accuray Announces Promotion of Suzanne Winter to President

  6/22/2021

  Accuray (NASDAQ: ARAY) announced today that Suzanne Winter has been promoted to president, effective as of July 1, 2021 .

• Accuray Expands CyberKnife® System Versatility with Integration of RaySearch's RayStation Treatment Planning System

  6/16/2021

  Accuray Incorporated announced the launch of RayStation* treatment planning support for the company's CyberKnife® M6™** and S7™** Robotic, Radiotherapy Systems.

• Accuray Expands Commercialization of ClearRT™ Helical Fan-Beam kVCT Imaging for the Radixact® System with CE Mark Certification

  6/10/2021

  Expands Global Access to Exceptional Quality Diagnostic-like CT Images for Medical Care Teams Using the Radixact System.

• Accuray Announces Convertible Notes Exchange and Subscription - May 07, 2021

  5/7/2021

  Accuray Incorporated announced that it has entered into privately negotiated agreements with the holders of its existing 3.75% senior convertible notes due 2022 to exchange an aggregate of $82.1 million principal amount of 2022 Notes for approximately $97.1 million aggregate principal amount of a new series of 3.75% senior convertible notes due 2026.

• Accuray Incorporated Reports Inducement Awards Under NASDAQ Listing Rules - May 06, 2021

  5/6/2021

  Accuray Incorporated reported, as required by NASDAQ Listing Rules, equity inducement awards to Jean-Philippe Pignol, M.D., Ph.D., the company's new Chief Medical & Technology Officer.

• Accuray Customers Achieve Top Scores in AAPM MArkerless Lung Target Tracking CHallenge (MATCH) Using Synchrony® Technology on the Radixact® and CyberKnife® Systems

  4/29/2021

  - American Association of Physicists in Medicine (AAPM) Grand Challenge MATCH event was designed to evaluate the potential to track lung tumor motion without fiducial markers in real-time during radiation therapy - Results demonstrate exceptional accuracy is achievable with the Accuray-only Synchrony® Lung Tracking™ with Respiratory Modeling Technology